Bonus Biogroup (Israel) Buy Hold or Sell Recommendation
| BONS Stock | ILS 10.80 0.10 0.93% |
Assuming the 90 days trading horizon and your complete indifference towards market risk, our recommendation regarding Bonus Biogroup is 'Strong Buy'. Macroaxis provides Bonus Biogroup buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BONS positions.
Check out Bonus Biogroup Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Bonus and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Bonus Biogroup. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Bonus |
Execute Bonus Biogroup Buy or Sell Advice
The Bonus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Bonus Biogroup. Macroaxis does not own or have any residual interests in Bonus Biogroup or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Bonus Biogroup's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Bonus Biogroup Trading Alerts and Improvement Suggestions
| Bonus Biogroup generated a negative expected return over the last 90 days | |
| Bonus Biogroup has accumulated 6.28 M in total debt. Bonus Biogroup has a current ratio of 0.34, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Bonus Biogroup until it has trouble settling it off, either with new capital or with free cash flow. So, Bonus Biogroup's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bonus Biogroup sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bonus to invest in growth at high rates of return. When we think about Bonus Biogroup's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (90.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bonus Biogroup has accumulated about 3.6 M in cash with (39.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 50.0% of the company shares are held by company insiders |
Bonus Biogroup Returns Distribution Density
The distribution of Bonus Biogroup's historical returns is an attempt to chart the uncertainty of Bonus Biogroup's future price movements. The chart of the probability distribution of Bonus Biogroup daily returns describes the distribution of returns around its average expected value. We use Bonus Biogroup price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Bonus Biogroup returns is essential to provide solid investment advice for Bonus Biogroup.
| Mean Return | -0.5 | Value At Risk | -3.97 | Potential Upside | 2.34 | Standard Deviation | 2.03 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Bonus Biogroup historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Bonus Biogroup Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Bonus Biogroup or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Bonus Biogroup's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Bonus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.59 | |
β | Beta against Dow Jones | 0.64 | |
σ | Overall volatility | 2.01 | |
Ir | Information ratio | -0.31 |
Bonus Biogroup Volatility Alert
Bonus Biogroup exhibits very low volatility with skewness of -0.09 and kurtosis of 1.87. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Bonus Biogroup's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Bonus Biogroup's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Bonus Biogroup Fundamentals Vs Peers
Comparing Bonus Biogroup's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Bonus Biogroup's direct or indirect competition across all of the common fundamentals between Bonus Biogroup and the related equities. This way, we can detect undervalued stocks with similar characteristics as Bonus Biogroup or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Bonus Biogroup's fundamental indicators could also be used in its relative valuation, which is a method of valuing Bonus Biogroup by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Bonus Biogroup to competition |
| Fundamentals | Bonus Biogroup | Peer Average |
| Return On Equity | -0.55 | -0.31 |
| Return On Asset | -0.0636 | -0.14 |
| Current Valuation | 169.66 M | 16.62 B |
| Shares Outstanding | 1.17 B | 571.82 M |
| Shares Owned By Insiders | 49.72 % | 10.09 % |
| Shares Owned By Institutions | 0.09 % | 39.21 % |
| Price To Book | 3.39 X | 9.51 X |
| EBITDA | (88.03 M) | 3.9 B |
| Net Income | (90.08 M) | 570.98 M |
| Cash And Equivalents | 3.6 M | 2.7 B |
| Cash Per Share | 0.01 X | 5.01 X |
| Total Debt | 6.28 M | 5.32 B |
| Current Ratio | 0.35 X | 2.16 X |
| Book Value Per Share | 0.12 X | 1.93 K |
| Cash Flow From Operations | (39.84 M) | 971.22 M |
| Earnings Per Share | (0.08) X | 3.12 X |
| Number Of Employees | 13 | 18.84 K |
| Beta | 1.4 | -0.15 |
| Market Capitalization | 223.15 M | 19.03 B |
| Total Asset | 104.32 M | 29.47 B |
| Z Score | 21.0 | 8.72 |
| Net Asset | 104.32 M |
Bonus Biogroup Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Bonus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Bonus Biogroup Buy or Sell Advice
When is the right time to buy or sell Bonus Biogroup? Buying financial instruments such as Bonus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Bonus Biogroup in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Heavy Metals Thematic Idea Now
Heavy Metals
Companies involved in mining, production, and distribution of various industrial metals and minerals. The Heavy Metals theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Heavy Metals Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Bonus Stock
Bonus Biogroup financial ratios help investors to determine whether Bonus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bonus with respect to the benefits of owning Bonus Biogroup security.